GET DAILY SIGNALSSS Innovations International (SSII) Prepares for Third-Quarter Earnings Release
Key Takeaways
- SS Innovations International is expected to report third-quarter 2026 results on or around November 3, 2026, based on its historical reporting schedule.
- Consensus estimates point to a loss of roughly $0.01 per share on revenue of approximately $14 million, following record second-quarter revenue of $13.9 million.
- The SSi Mantra installed base reached 224 systems across 12 countries as of June 30, 2026, making system installations and procedure volumes the core metrics to watch.
- Investors remain focused on regulatory catalysts, including U.S. FDA 510(k) clearance and EU CE marking certification.
- The company held $13.6 million in cash and cash equivalents and no long-term debt as of June 30, 2026, supporting its commercialization push.
Why the Upcoming Report Matters
SS Innovations International (SSII) operates as a commercial-stage surgical robotics company, with its flagship SSi Mantra system designed to improve access to robotic surgery globally. The firm has shown strong top-line momentum, with revenue climbing 39.4% year over year to a record $13.9 million in the second quarter of 2026. This earnings release will help clarify whether that pace can hold as installations expand in India and additional markets. I’m watching closely for any fresh details on U.S. and European regulatory progress, which could open larger opportunities. With shares well below their 52-week high, the report serves as a useful checkpoint on execution and the longer-term path to profitability.
What Analysts Expect
Current consensus calls for a net loss of about $0.01 per share on revenue near $14 million for the third quarter of 2026. That would compare with third-quarter 2025 revenue of roughly $12.8 million and a $0.02 per share loss, pointing to continued double-digit revenue growth even while the company stays unprofitable. For context, second-quarter 2026 results showed $13.9 million in revenue and a $2.7 million net loss, or $0.01 per diluted share, which beat the revenue estimate of around $12 million. Gross margin stood at 50.9% in that quarter and will be worth monitoring, along with new SSi Mantra installations that grew 30.4% to 30 systems. Past stock reactions have been mixed given the combination of growth and ongoing losses, so evidence of scale and improving cash use will be key.
I also checked comparable names using Tickeron’s AI Screener to see how SSII stacks up on technical and fundamental metrics.
Market Sentiment Heading Into the Print
Investor tone appears measured. Shares of SSII have fallen from their 52-week high near $9 and have traded toward the lower end of their range despite the revenue gains. Concerns center on persistent net losses, margin pressure, and the impact of recent capital raises, including a private placement that brought in about $18.6 million in gross proceeds. Still, the growing installed base, rising procedure volumes, and a Buy rating with a $7 price target from Lucid Capital support a constructive longer-term view on SSi Mantra adoption. The release will test whether faster installations can ease worries about profitability and cash use.
Key Items to Track Going Forward
Regulatory milestones stand out as the primary catalyst. SSII expects the FDA to finish its 510(k) review for the SSi Mantra by the end of the first quarter of 2027 and anticipates securing EU CE marking by the close of 2026. Success on either front would meaningfully broaden the company’s addressable market.
Installation and procedure growth will also be central. The cumulative base reached 224 systems with more than 12,000 surgeries completed as of June 30, 2026, while telesurgery progress continues to strengthen the platform’s clinical profile.
Finally, balance-sheet health and cash burn deserve attention. With $13.6 million in cash at mid-2026 and ongoing losses, the ability to support expansion without additional dilution remains important. Trends in gross margin and spending tied to regulatory work and market entry will help gauge progress toward profitability.
Using AI Tools for Deeper Analysis
When evaluating names like SSII, I find it helpful to run quick scans for comparable setups and technical signals. Tickeron’s AI Screener lets me filter across fundamentals, volatility, and pattern data in one place, which keeps the research process efficient without replacing my own judgment on the numbers.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SSII in -6.64% downward trend, falling for three consecutive days on October 23, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where SSII declined for three days, in 120 of 130 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SSII as a result. In 67 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SSII entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where SSII's RSI Oscillator exited the oversold zone, 23 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 31 of 46 cases where SSII's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 67%.
The Moving Average Convergence Divergence (MACD) for SSII just turned positive on October 27, 2026. Looking at past instances where SSII's MACD turned positive, the stock continued to rise in 29 of 39 cases over the following month. The odds of a continued upward trend are 74%.
Following a +11.11% 3-day Advance, the price is estimated to grow further. Considering data from situations where SSII advanced for three days, in 62 of 95 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
SSII may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.846) is normal, around the industry mean (3.837). P/E Ratio (0.000) is within average values for comparable stocks, (2.078). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (12.887) is also within normal values, averaging (40.124).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. SSII’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 93 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SSII’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry MedicalNursingServices
Advertisement